Search research articles
Contact Us
Filters
Showing results (71-80 of 102) with videos related to
Page
of 11
Sort By:
JCO Precision Oncology
|
February 1, 2022
Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer
Kanwal Raghav, Jonathan M Loree, Jeffrey S Morris, et al.
JCO Precision Oncology
|
July 12, 2021
Comprehensive Clinical and Molecular Characterization of <i>KRAS</i> <sup>G12C</sup>-Mutant Colorectal Cancer
Jason T Henry, Oluwadara Coker, Saikat Chowdhury, et al.
Cancer Medicine
|
August 29, 2018
Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
Dalia Elganainy, Emma B Holliday, Cullen M Taniguchi, et al.
JCO Precision Oncology
|
September 14, 2020
Targeting <i>ERBB2</i> (<i>HER2</i>) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications
Ecaterina E Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, et al.
Plos One
|
March 8, 2017
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer
Amir Mehrvarz Sarshekeh, Shailesh Advani, Michael J Overman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2017
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
Christine M Parseghian, Nila U Parikh, Ji Yuan Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 29, 2017
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes
Jonathan M Loree, Allan A L Pereira, Michael Lam, et al.
Journal of the National Cancer Institute
|
May 18, 2023
Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study
Ryan W Huey, Aakash Tushar Shah, Honey V Reddi, et al.
The Lancet. Oncology
|
May 7, 2021
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav, et al.
Hepatology (Baltimore, Md.)
|
September 15, 2020
HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk
Jeffrey S Morris, Manal M Hassan, Ye Emma Zohner, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 102) with videos related to
Sort By:
Page
of 11
JCO Precision Oncology
|
February 1, 2022
Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer
Kanwal Raghav, Jonathan M Loree, Jeffrey S Morris, et al.
JCO Precision Oncology
|
July 12, 2021
Comprehensive Clinical and Molecular Characterization of <i>KRAS</i> <sup>G12C</sup>-Mutant Colorectal Cancer
Jason T Henry, Oluwadara Coker, Saikat Chowdhury, et al.
Cancer Medicine
|
August 29, 2018
Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
Dalia Elganainy, Emma B Holliday, Cullen M Taniguchi, et al.
JCO Precision Oncology
|
September 14, 2020
Targeting <i>ERBB2</i> (<i>HER2</i>) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications
Ecaterina E Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, et al.
Plos One
|
March 8, 2017
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer
Amir Mehrvarz Sarshekeh, Shailesh Advani, Michael J Overman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2017
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
Christine M Parseghian, Nila U Parikh, Ji Yuan Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 29, 2017
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes
Jonathan M Loree, Allan A L Pereira, Michael Lam, et al.
Journal of the National Cancer Institute
|
May 18, 2023
Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study
Ryan W Huey, Aakash Tushar Shah, Honey V Reddi, et al.
The Lancet. Oncology
|
May 7, 2021
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav, et al.
Hepatology (Baltimore, Md.)
|
September 15, 2020
HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk
Jeffrey S Morris, Manal M Hassan, Ye Emma Zohner, et al.
Page
of 11